Please login to the form below

Not currently logged in
Email:
Password:

Shire eyes 6 product launches by end of 2006

British firm reports a third-quarter net loss after TKT acquisition charges

British-based Shire Pharmaceuticals said it aims to launch six new products by the end of 2006, after reporting a third-quarter net loss of $624.2m (£352m) due to higher costs of developing new drugs and charges related to its recent acquisition of US biotech Transkaryotic Therapies (TKT).

The company said potential 2006 launches for NRP104 and Daytrana for attention deficit hyperactivity disorder (ADHD) and I2S for Hunter syndrome, a rare hereditary disorder, could bump up marketing costs to $700m next year from $640m in 2005.

However, analyst Frances Cloud at Nomura described the chances of the firm launching six products in the next 14 months were "quite unrealistic".

"In the projections, it is assumed that the Food and Drug Administration (FDA) will approve everything outright on or before the PDUFA [Prescription Drug Users Fee Act] date," she said. "By looking at average statistics coming out of the FDA itís pretty clear that the FDA does not approve things by the PDUFA dates. It very often issues an approvable letter and asks for new data."

Shire also said it would continue to protect its best-selling ADHD drug, Adderall XR, from generic competition. It has filed lawsuits against Barr Pharmaceuticals and Impax Laboratories, alleging that their respective products infringe one of Adderall XRís patents.

Cloud said that of all Shireís new products, NRP104 had the most potential to be a big-selling drug: "It will replace Adderall if it gets to market."

In the nine months to September 30, Shire made a pre-tax profit of $430m ($344m) on turnover of $1.13bn ($989m).

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics